Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Hyperglycaemia is associated with an elevated risk of mortality in community-acquired pneumonia, stroke, acute myocardial infarction, trauma and surgery, among other conditions. In this study, we examined the relationship between fasting blood glucose (FBG) and 28-day mortality in coronavirus disease 2019 (COVID-19) patients not previously diagnosed as having diabetes. We conducted a retrospective study involving all consecutive COVID-19 patients with a definitive 28-day outcome and FBG measurement at admission from 24 January 2020 to 10 February 2020 in two hospitals based in Wuhan, China. Demographic and clinical data, 28-day outcomes, in-hospital complications and CRB-65 scores of COVID-19 patients in the two hospitals were analysed. CRB-65 is an effective measure for assessing the severity of pneumonia and is based on four indicators, i.e. confusion, respiratory rate (>30/min), systolic blood pressure (≤90 mmHg) or diastolic blood pressure (≤60 mmHg), and age (≥65 years). Six hundred and five COVID-19 patients were enrolled, including 114 who died in hospital. Multivariable Cox regression analysis showed that age (HR 1.02 [95% CI 1.00, 1.04]), male sex (HR 1.75 [95% CI 1.17, 2.60]), CRB-65 score 1–2 (HR 2.68 [95% CI 1.56, 4.59]), CRB-65 score 3–4 (HR 5.25 [95% CI 2.05, 13.43]) and FBG ≥7.0 mmol/l (HR 2.30 [95% CI 1.49, 3.55]) were independent predictors for 28-day mortality. The OR for 28-day in-hospital complications in those with FBG ≥7.0 mmol/l and 6.1–6.9 mmol/l vs <6.1 mmol/l was 3.99 (95% CI 2.71, 5.88) or 2.61 (95% CI 1.64, 4.41), respectively. FBG ≥7.0 mmol/l at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes. Glycaemic testing and control are important to all COVID-19 patients even where they have no pre-existing diabetes, as most COVID-19 patients are prone to glucose metabolic disorders. Graphical abstract Graphical abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationZhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Self-citationYang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Self-citationIntensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Self-citationKDIGO Clinical Practice Guidelines for Acute Kidney Injury
Khwaja, A. (2012) · Nephron Clinical Practice · doi:10.1159/000339789 · Cited by 8,014
Intensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119 · cited 1×
“The debate over this issue remains, and a study published in 2009 found that intensive glycaemic control could increase mortality in adults in ICUs, but increasing target glucose levels to 10 mmol/l could reduce mortality [34].”
Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study
Shi, H., Han, X., Jiang, N., Cao, Y., Alwalid, O., Gu, J., Fan, Y., & Zheng, C. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30086-4 · Cited by 3,664
Intensive insulin therapy in the medical ICU
Van den Berghe, G., Wilmer, A., Hermans, G., Meersseman, W., Wouters, P. J., Milants, I., Van Wijngaerden, E., Bobbaers, H., & Bouillon, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052521 · Cited by 3,639
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Zhu, L., She, Z.-G., Cheng, X., Qin, J.-J., Zhang, X.-J., Cai, J., Lei, F., Wang, H., Xie, J., Wang, W., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.021 · Cited by 1,602
Yang, J. K., Feng, Y., Yuan, M. Y., Yuan, S. Y., Fu, H. J., Wu, B. Y., Sun, G. Z., Yang, G. R., Zhang, X. L., Wang, L., et al. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01861.x · Cited by 794
Bode, B., Garrett, V., Messler, J., McFarland, R., Crowe, J., Booth, R., & Klonoff, D. C. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820924469 · Cited by 766 · cited 2×
“Previous studies have shown that diabetes and acute uncontrolled hyperglycaemia (defined as blood glucose >10 mmol/l twice within any 24 h period) are related to morbidity and/or mortality from COVID-19 [13, 21, 25].”
BackgroundAssociation Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China
Bragg, F., Holmes, M. V., Iona, A., Guo, Y., Du, H., Chen, Y., Bian, Z., Yang, L., Herrington, W., Bennett, D., et al. (2017) · JAMA · doi:10.1001/jama.2016.19720 · Cited by 497
Gregg, E. W., Cheng, Y. J., Srinivasan, M., Lin, J., Geiss, L. S., Albright, A. L., & Imperatore, G. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30314-3 · Cited by 480
McAlister, F. A., Majumdar, S. R., Blitz, S., Rowe, B. H., Romney, J., & Marrie, T. J. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.810 · Cited by 441
Ewig, S., Birkner, N., Strauss, R., Schaefer, E., Pauletzki, J., Bischoff, H., Schraeder, P., Welte, T., & Hoeffken, G. (2009) · Thorax · doi:10.1136/thx.2008.109785 · Cited by 403
Ehrlich, S. F., Quesenberry, C. P., Van Den Eeden, S. K., Shan, J., & Ferrara, A. (2010) · Diabetes Care · doi:10.2337/dc09-0880 · Cited by 355
Diabetes and infection: assessing the association with glycaemic control in population-based studies
Pearson-Stuttard, J., Blundell, S., Harris, T., Cook, D. G., & Critchley, J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00379-4 · Cited by 308
Impact of admission hyperglycemia on hospital mortality in various intensive care unit populations*
Whitcomb, B. W., Pradhan, E. K., Pittas, A. G., Roghmann, M.-C., & Perencevich, E. N. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000189741.44071.25 · Cited by 224
Lepper, P. M., Ott, S. R., Nüesch, E., von Eynatten, M., Schumann, C., Pletz, M. W., Mealing, N. M., Welte, T., Bauer, T. T., Suttorp, N., et al. (2012) · BMJ · doi:10.1136/bmj.e3397 · Cited by 163
Cerebrovascular accidents in Ghana
Haddock, D. R. W. (1970) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(70)90141-0 · Cited by 97
Stress Hyperglycemia in Critically Ill Patients: Insight Into Possible Molecular Pathways
Bar‐Or, D., Rael, L. T., Madayag, R. M., Banton, K. L., Tanner, A. H., Acuna, D. L., Lieser, M. J., Marshall, G. T., Mains, C. W., & Brody, E. N. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00054 · Cited by 95
Diabetes Mellitus, Hypertension, and Death among 32 Patients with MERS-CoV Infection, Saudi Arabia
Alanazi, K. H., Abedi, G. R., Midgley, C. M., Alkhamis, A. M., Alsaqer, T. A., Almoaddi, A., Algwizani, A. R., Ghazal, S., Assiri, A. M., Jokhdar, H., et al. (2019) · Emerging infectious diseases · doi:10.3201/eid2601.190952 · Cited by 47
Burcelin, R., & Amar, J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.75 · Cited by 7
Topical glucocorticoids and risk of type 2 diabetes mellitus
Johns, E. C., & Reynolds, R. M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0212-8 · Cited by 5
Schneider, G. T., & Maier, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-28852-5_18 · Cited by 4
Cited by
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19
Stefan, N., Birkenfeld, A. L., & Schulze, M. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00462-1 · Cited by 452
COVID-19, Hyperglycemia, and New-Onset Diabetes
Khunti, K., Del Prato, S., Mathieu, C., Kahn, S. E., Gabbay, R. A., & Buse, J. B. (2021) · Diabetes Care · doi:10.2337/dc21-1318 · Cited by 320
Coate, K. C., Cha, J., Shrestha, S., Wang, W., Gonçalves, L. M., Almaça, J., Kapp, M. E., Fasolino, M., Morgan, A., Dai, C., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.006 · Cited by 177
COVID-19 and Diabetes: A Collision and Collusion of Two Diseases
Feldman, E. L., Savelieff, M. G., Hayek, S. S., Pennathur, S., Kretzler, M., & Pop-Busui, R. (2020) · Diabetes · doi:10.2337/dbi20-0032 · Cited by 136
“COVID-19 can also induce hyperglycemia in patients without diabetes, secondary to infection, which increases the risk of critical disease (34,35).”
Background
Metadata
- Authors
- Wang, S., Ma, P., Zhang, S., Song, S., Wang, Z., Ma, Y., Xu, J., Wu, F., Duan, L., Yin, Z., Luo, H., Xiong, N., Xu, M., Zeng, T., & Jin, Y.
- Venue
- Diabetologia
- Published
- 2020-07-10
- Volume
- 63
- Issue
- 10
- Pages
- 2102-2111
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W3041005642
- Cited by
- 325
- References
- 27
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.